MIAMI, August 28, 2025 — Leads & Copy — Pasithea Therapeutics Corp. (NASDAQ: KTTA) will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City, September 8-10, 2025.
Pasithea CEO, Dr. Tiago Reis Marques, will present live, and management will be available for one-on-one meetings. The presentation is scheduled for September 10, 2025, at 2:30 PM ET at the Lotte New York Palace Hotel; interested parties can register for the webcast.
Pasithea is researching and developing PAS-004, a next-generation macrocyclic MEK inhibitor for RASopathies, MAPK pathway-driven tumors, and other diseases. PAS-004 is in Phase 1 clinical trials for advanced cancer patients (NCT06299839) and a Phase 1/1b clinical trial for adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).
Patrick Gaynes, Corporate Communications, pgaynes@pasithea.com
Source: Pasithea Therapeutics Corp.
